40
Views
73
CrossRef citations to date
0
Altmetric
Original Article

Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Patients Treated with Fludarabine

, , , , , & show all
Pages 63-68 | Received 02 Jan 1993, Published online: 01 Jul 2009

References

  • Gale R. P., Foon K. A. Biology of chronic lym-phocytic leukemia. Sem. Hematol. 1987; 4: 209
  • Hansen M. M. Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand. J. Haematol. 1973; 18: 71
  • Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: New insight into biology and therapy. Ann. Intern. Med. 1990; 113: 525
  • Lewis F. B., Schwartz R. S., Damashek W. X-radiation and alkylating agents as possible “trigger” mechanism in the autoimmune complications of malignant lym-phoproliferative diseases. Clin. Exper. Immunol. 1966; 1: 3
  • Catovsky D., Foa R. B-cell chronic lymphocytic leukemia. The Lymphoid Leukaemias. Butterworth & Co. Ltd., London 1990; 73–112
  • Thompson-Moya L., Martin T., Heuft H. G., Neubauer A., Herrmann R. Case report: Allergic reaction with immune hemolytic anemia resulting from chlorambucil. Am. J. Hematol. 1989; 32: 230
  • French Cooperative Group on Chronic Lyrnphocytic Leukemia. Long term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br. J. Haematol. 1989; 73: 334
  • Keating M. J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; 17: 49
  • Boldt D. H., Von Hoff D. D., Kuhn J. G., Hersh M. Effect on human peripheral lymphocytes of in vivo administration of 9–B-D-arabinofuranosyl-2–fluoroadenine-5'-monophosphate (NSC 312887). a new purine antimetabolite. Cancer Res. 1984; 44: 4661
  • Robertson L., Huh Y., Hirsch-Ginsberg C., Kantajian H., O'Brien S., Koller C., McCredie K., Keating M. J. Clinical, immunophenotypic, and molecular analysis of the completeness of response in chronic lymphocytic leukemia after fludarabine. Blood 1990; 76: 314a, (#1245) (abstr)
  • Gale R. P. A review of disordered immunity and hy-pogamma-globulinemia in chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction, R. P. Gale, K. R. Rai. Alan R. Liss, New York, NY 1987; 411
  • Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am. J. Hematol. 1988; 29: 152
  • Hamblin T. J., Oscier D. G., Young B. J. Au-toimmunity in chronic lymphocytic leukemia. J. Clin. Pa-thol. 1986; 39: 713
  • De Rossi G., Granati L., Girelli G., Gandolfo G., Arista M. C., Martelli M., Conti L., Marini R., La Tagliata R., Leone R., Mandelli F. Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol. 1988; 30: 403
  • Borche L., Lim A., Binet J. L., Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural antibodies. Blood 1990; 76: 562
  • Dighiero G. An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL. Nouv. Rev. Fr. Hematol. 1988; 30: 283
  • Dighiero G., Hart S., Lim A., Miller R. A., Borche L., Levy R. Evidence that B-cell malignancies frequently involve autoreactive B-cells. Blood 1990; 76: 346a, (#1376) (abstr)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.